 NEWARK, Calif., June 18, 2021 PRNewswire -- Protagonist Therapeutics, Inc. Nasdaq:PTGX, a clinical stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 3,503,311 shares of its common stock, including 456,953 shares sold pursuant to the underwriters exercise in full of their green shoe option to purchase additional shares, at a price to the public of 37.75 per share. 